EPO patent interferences
Between Amgen and Genetics Institute resolved in Amgen's favor, on Dec. 5. The interferences, declared by the Patent & Trademark Office in May 1989. The first interference involved Amgen's 4,703,008 patent for host cells, DNA sequence and vector producing erythropoietin (Epogen), which issued in Oct. 1987, and a similar patent application filed by Genetics Institute as well as pending applications by Amgen and Genetics Institute for an EPO process patent and a patent for the recombinant product. Amgen said that as a result of the decision it expects to receive EPO process and product patents.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth